{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-230659","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.260568+00:00","generated_at":"2026-06-10T22:46:45.784749+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tempest Therapeutics president Tom Dubensky resigns; CEO Stephen Brady to assume president role","bullets":["Tom Dubensky resigned as president and board member effective Sep 2, 2023; will transition to advisor role on Sep 15, 2023.","Resignation not due to any disagreement with Tempest on operations, policies, or practices.","CEO Stephen Brady will be appointed as president and CEO effective Sep 15, 2023; his responsibilities unchanged.","Dubensky expected to enter consulting agreement: $8,000 retainer for initial period (Sep 15–Oct 15), then $500/hour for services.","Consulting period expected until at least Dec 15, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-230659","json":"https://secwatch.observer/filing/0001193125-23-230659.json","markdown":"https://secwatch.observer/filing/0001193125-23-230659.md","text":"https://secwatch.observer/filing/0001193125-23-230659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/d532461d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:46:45.784749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4cb24c028","claim":"Stephen Brady was appointed as President and Chief Executive Officer at Tempest Therapeutics, Inc..","evidence_excerpt":"the Board will appoint Stephen Brady, the Company’s chief executive officer, as president and chief executive officer effective as of the Separation Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f9d031ff99","claim":"Tom Dubensky resigned as President and member of the Board of Directors at Tempest Therapeutics, Inc..","evidence_excerpt":"On September 2, 2023, Tom Dubensky, Ph.D. resigned from his role as president and member of the Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}